Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test.
Buprenorphine is a mixed opioid receptor agonist-antagonist. Recently, buprenorphine was reported to act as an agonist to opioid receptor like-1 (ORL1) receptor. In the present study, we examined the role of spinal and supraspinal mu receptors and spinal and supraspinal ORL1 receptors in producing an analgesic effect by intrathecal (i.t.), intracerebroventricular (i.c.v.), or i.p. administration of buprenorphine in the rat formalin test. Male rats were prepared with i.t. catheters or i.c.v. injection cannulas. The paw formalin injection (50 microl of 5% formalin) induces biphasic flinching (phase 1, 0-6 min; phase 2, 10-60 min) of the injected paw. Buprenorphine, naloxone (a mu-opioid receptor antagonist), or (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J113397) (an ORL1 receptor-selective antagonist) was administered i.t., i.c.v., or i.p.. Intrathecal, i.c.v., or i.p. injection of buprenorphine produces an analgesic effect in a dose-dependent manner. The effect of i.c.v. buprenorphine was antagonized by i.c.v. naloxone or i.c.v. J113397, and the effect of i.t. buprenorphine was antagonized by i.t. naloxone or i.t. J113397. The effect of i.p. buprenorphine was antagonized by i.p. or i.t. naloxone but not by i.c.v. naloxone. The analgesic effect of i.p. buprenorphine was enhanced by i.p. J113397 or i.c.v. J113397. Intraperitoneal, but not i.t. or i.c.v., buprenorphine decreased the number of Fos-like immunoreactivity positive neurons in the L4-L5 spinal dorsal horn. These data indicated that buprenorphine affects nociceptive processing by acting at both supraspinal and spinal mu and ORL1 receptors. The analgesic effect of systemically administered buprenorphine was suppressed by the concomitant activation of supraspinal ORL1 receptor.
Yamamoto
Tatsuo
T
Department of Anesthesiology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260, Japan. yamamotot@faculty.chiba-u.jp
Shono
Koyo
K
Tanabe
Serabi
S
D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002047:Buprenorphine / Q000494:pharmacology*; D008297:Male; D009292:Narcotic Antagonists; D010147:Pain Measurement / Q000187:drug effects* / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000819:agonists / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000094942:Nociceptin Receptor
D000701:Analgesics, Opioid; D002047:Buprenorphine; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D000094942:Nociceptin Receptor; C000722285:Oprl1 protein, rat